NMDA receptor antagonists for neuroprotection

US8420680B2 · kind B2 · utility

Assignees

• EMORY UNIVERSITY · US
• NEUROP, INC. · US

Inventors

• Dennis C. Liotta · Atlanta, US
• James P. Snyder · Atlanta, US
• Stephen F. Traynelis · Decatur, US
• Lawrence Wilson · Mason, US
• Cara Mosley · Atlanta, US
• Raymond J. Dingledine · Atlanta, US
• Yesim Altas Tahirovic · Atlanta, US
• Scott Myers · Atlanta, US

Key dates

• Filing date: Jun 30, 2008
• Grant date: Apr 16, 2013
• Expiry date: Jun 14, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D295/088
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of disorders associated with NMDA receptor activity, including neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof are provided:wherein:each (L)k-Ar1 is a substituted or unsubstituted, mono or bicyclic aryl or heteroaryl; W is a bond, alkyl, or alkenyl; X is a bond, NR1 or O and each R1 and R2 is independently H, alkyl, alkenyl or aralkyl or R1 and R2 taken together form a 5-8 membered ring; R3−R6 are selected from certain specific substituents or a carbonyl; Y is a bond, O, S, SO, SO2, CH2, NH, N(alkyl), or NHC(═O); and Z is OH, NR6R7, NR8SO2(alkyl), NR8C(O)NR6R7, NR8C(O)O(alkyl), NR8-dihydrothiazole, or NR8-dihydroimidazole or wherein Z can fuse with Ar2 to form selected heterocycles.